In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the ...

CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by ...

Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...

The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.

The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...

The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

Dr Choo Mei Sze (PhD Development Psychology) is glowing. At 38, the mother-of-one still carries a fresh, youthful ...

Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...

Scientists showed that using new molecules that block an immune "checkpoint" could stimulate a "strong" anti-tumor immune ...

Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative month for cancer treatment with ...

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along ...